Gilead Executive VP-R&D Norbert Bischofberger: An Interview With “The Pink Sheet” DAILY (Part 2 of 3)
This article was originally published in The Pink Sheet Daily
Executive Summary
Bischofberger discusses how darusentan could complement recently approved Letairis in the hypertension market, and how Gilead plans to develop its integrase inhibitor elvitegravir, a potential competitor to Merck’s Isentress.